| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department in Turku,* National Public Health Institute and MediCity Research Laboratory, University of Turku, Turku; the Department of Epidemiology and Health Promotion, KTL-National Public Health Institute, Helsinki; the Department of Public Health, University of Helsinki, Helsinki; the Department of Pediatrics, the University of Oulu, Oulu, the Hospital for Children and Adolescents, Oulu, and the University of Helsinki, Helsinki; and the Turku Positron Emission Tomography Center,¶ University of Turku, Turku, Finland
Vascular adhesion protein-1 (VAP-1) is one of the molecules on the endothelial cell membrane, which may guide inflammatory cells into atherosclerotic lesions. This dual function molecule may also contribute to the pathogenesis of atherosclerosis and other vasculopathies via its enzymatic activity that oxidizes primary amines to produce their corresponding aldehydes, hydrogen peroxide, and ammonium. Because VAP-1 also exists in a soluble form, we analyzed its potential usefulness as a biomarker to monitor and predict the extent of ongoing atherosclerotic processes. Soluble VAP-1 (sVAP-1) levels were determined from the sera of 136 Finnish men with established coronary heart disease and in 275 controls using sandwich enzyme immunoassays and correlated to multiple risk factors for coronary events. Intriguingly, sVAP-1 showed a statistically significant correlation with diabetes in both cohorts. We then collected patients with type 1 diabetes and observed that sVAP-1 levels were highly elevated when the patients were metabolically compromised. On normalization of their blood glucose and ketone body levels by exogenous insulin, their sVAP-1 concentration rapidly decreased to control levels. Intravenous glucose tolerance and hyperinsulinemic clamp tests further showed that elevation of blood glucose per se did not increase sVAP-1 levels, but rather, sVAP-1 was inversely correlated with circulating insulin concentrations. In conclusion insulin appears to regulate shedding or clearance of VAP-1, and an increase in sVAP-1 because of absolute or relative insulin deficiency may be directly involved in the pathogenesis of diabetic angiopathy.
This article has been cited by other articles:
 |
|
 |
|
  S. Jalkanen and M. Salmi VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 18 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Huber, R. L. VanGilder, and K. A. Houser Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2660 - H2668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K. E. J. Airaksinen, J. Knuuti, R. Parkkola, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E282 - E290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Stolen, G. G. Yegutkin, R. Kurkijarvi, P. Bono, K. Alitalo, and S. Jalkanen Origins of Serum Semicarbazide-Sensitive Amine Oxidase Circ. Res., July 9, 2004; 95(1): 50 - 57. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
